Safusidenib for IDH1-mutant glioma after vorasidenib failure
Part of Cancer clinical trials.
This study tests a new drug called safusidenib for people with IDH1-mutant gliomas (a type of brain tumor) that kept growing even while on the previous drug vorasidenib. The goal is to see if it can control the tumor safely and effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of brain tumor called IDH-mutant glioma (including astrocytoma or oligodendroglioma) that is grade 2 or 3.
- You have a specific change in the IDH1 gene (called an R132 mutation).
- You have had at least one surgery for your brain tumor (like a biopsy or partial removal).
- You took the drug vorasidenib for your tumor, but the tumor continued to grow during treatment.
- You are not currently in urgent need of chemotherapy or radiation.
- You have not received any other cancer treatment for your glioma besides surgery and vorasidenib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of advanced brain cancer called IDH-mutant astrocytoma. It is for patients who have not had previous treatments like chemotherapy or radiation and whose tumors have certain genetic features.
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
This trial tests a drug called safusidenib in people with a slow-growing brain tumor (grade 2 glioma) that has a specific IDH1 gene mutation. The goal is to see if the drug can help control the tumor without needing chemotherapy or radiation right away.
This trial tests the drug vorasidenib for people with a slow-growing brain tumor (Grade 2 glioma) that has an IDH mutation. The goal is to see how well the drug works and how it affects your quality of life.
This trial tests a targeted drug, vorasidenib, for people with a specific type of slow-growing brain tumor (low-grade glioma) that has come back or is still present after surgery. The drug is guided by a special PET scan to see if it reaches the tumor.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.